Preparing for Pivotal Product Manufacturing: Scale-up Considerations for Large-Market Allogeneic Cell Therapies
Time: 1:00 pm
day: Conference Day Two
Details:
- Addressing significant unmet need in cancer and autoimmune disease indications with Atara’s robust pipeline of investigational allogeneic CAR-T immunotherapies
- Preparing for pivotal product manufacturing from the perspective of a commercialized cell therapy company
- Moving from static to suspension cell culture production to enable scalability of T-cell therapy manufacturing and favorable cost-of-goods
